NCT04417088 — "Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy" trial site landscape

Public-registry site landscape for NCT04417088, “Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy”, a Recurrent Glioblastoma study sponsored by InSightec. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT04417088 (registry record)
Study title	Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
Official title	Assessment of Safety and Feasibility of Exablate Type 2 for Blood-Brain Barrier Disruption (BBBD) With Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy
Sponsor	InSightec
Condition(s)	Recurrent Glioblastoma
Phase	PHASE1 / PHASE2
Listed sites	4
Site countries	United States

Patient-friendly overview of this study: eichor.com/study/NCT04417088.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT04417088 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →